Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Recordati reveals phase III data for pitavastatin

Recordati reveals phase III data for pitavastatin

23rd September 2009

Recordati has unveiled the findings of a phase III clinical trial into pitavastatin, which revealed that the drug is a valid and effective long-term treatment option for patients with primary hypercholesterolaemia or combined dyslipidaemia.

The outcome also discovered that pitavastatin is non-inferior to first-line treatments atorvastatin and simvastatin and demonstrates sustained efficacy and tolerability over a 52-week period.

Dr Leiv Ose, an investigator of the trial, said: “Many patients do not reach LDL-C (low density lipoprotein cholesterol targets) with current therapies due to a number of factors, especially non-compliance, and a statin which has the potential to improve long-term treatment is welcomed.”

Pitavastatin received FDA approval for the primary treatment of hypercholesterolemia and combined dyslipidemia in August and is expected to launch in the US early next year.

In other Recordati news, the firm announced its financial results for the first half of 2009 during the summer and revealed that its revenues reached 379.3 million euros (324.8 million pounds).

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.